BACKGROUND/AIM Studies on physicians and other health care professionals indicate that attitudes towards and beliefs in their work with patients, can affect the quality of health care, and patients' behaviour and compliance, thus an instrument is needed to survey pharmacists as healthcare providers. The aim of this study was to describe the development and psychometric validation of a survey instrument to assess attitudes and beliefs of pharmacists toward their work with patients (Pharmacists' Attitudes and Beliefs Scale, PABS). The aim of this research was to determine the reliability, validity and factor structure of a newly constructed instrument - PABS. METHODS The statements from the cognitive, affective, and behavioral areas were identified by literature review and selected to cover the behavior of pharmacists in providing pharmaceutical care at community settings. The initial 5-point Likert type scale of 30 items was constructed and after initial validation its revised form developed. The reliability, construct validity and factor structure of the scale were established. RESULTS The reliability of the scale was determined by the method of internal consistency, on a convenient sample of 123 community pharmacists. The Cronbach's alpha coefficient was 0.67. Factor analysis of principal components was performed and 7 factors with latent roots greater than 1 were extracted, explaining 64.92% of total variance, a single 30.84%, 8.20%, 6.55%, 5.63%00, 5.01%, 4.68% and 4.01%. Based on the results of factor analysis in the development of the scale, some items in the scale were excluded (totally 7), so that the revised form of the PABS contained a total of 23 items. CONCLUSION The initial PABS scale did not meet theoretical statistical criteria for reliability (Cronbach's alpha coefficient was < 0.7), but the findings indicated its potentially acceptable construct validity. The results support its use as a research tool to assess the behavior of pharmacists in daily practice, and provide its use as an indicator of quality in delivering pharmaceutical care.

INTRODUCTION Healthcare enlightenment and healthcare culture in Vranje and its region were under Turkish influence until the liberation in 1878, when the organisation of education, schooling and healthcare were initiated in the Vranje region OBJECTIVE The aims of this study were to shed light on the beginning of the development of pharmaceutical personnel, and their contribution to healthcare culture development in Vranje and its region, with a focus on healthcare legislation and its impact on pharmaceutical service availability, and the analysis of pharmaceutical personnel development within the healthcare services. METHODS We used the methods of documentation analysis and the desk analysis of the secondary information. RESULTS At the beginning of the 19th century healthcare services in Vranje were still inexistent. After the liberation from the Turks, Naum's medical office with pharmacy was opened in Vranje. Although it did not comply with regulations, it presented the only formal source of supply of medications and sanitary material, and as such it gave its contribution to healthcare service at that time in Vranje. Mr ph. Stevan Varjacic, 1st class pharmacy assistant, worked at a temporary hospital from 1880 until January 1881, suppling with medications soldiers and residents of Vranje. The development of pharmaceutical schooling began in 1883, when a pharmacy was opened by the pharmacist Velimir Karic according to the Law on Healthcare Organisation and People's Healthcare Maintenance. By the end of the 1930s there were ten civilian healthcare institutions in Vranje, even three of which were pharmacies. By the end of 1948, they were nationalized, and were renamed the City National Pharmacy of Vranje. CONCLUSION By the end of the 10th century, passing of the legislation on the regulations of pharmaceutical industry within healthcare services had an impact on Vranje that resulted in opening pharmacies with educated pharmaceutical personnel. Pharmacy owners changed, and the quality and continuity of medical supplies was always secured.

This paper discusses how a system approach to management can be used for the development and implementation of an integrated management system (IMS) in a company producing medicinal products. It is argued in the paper that approaches to the solutions of how to integrate management systems all require two elements: a conceptual model and a supporting methodology. Although a large number of models has been developed that could provide the basis for integration, development of methodologies to achieve fully integrated systems is still stagnating. This paper presents the IMS model that can be used to integrate the requirements of existing and upcoming standards in the pharmaceutical industry, followed by a discussion on the issue of the IMS methodology.

INTRODUCTION Every clinical trial has to meet all ethical criteria in addition to the scientific ones. The basic ethical principles in the clinical trials are the following: nonmaleficence, beneficence, respect for autonomy and the principle of justice. OBJECTIVE The aim of the study was to analyse clinical cases with the outcomes leading to the changes in regulatory-ethical framework related to the clinical trials, as well as the outcomes of key clinical trials that influenced the introduction of the ethical principles into clinical trials. METHODS This was a descriptive research (methods of analysis and documentation; desk analysis of the secondary data). RESULTS By analysing the cases from the secondary sources as well as clinical and ethical outcomes, it may be noticed that the codes, declarations and regulations have been often preceded by certain events that caused their adoption. Moral concern and public awareness of the ethical issues have initiated not only the development of numerous guidelines, codes, and declarations, but also their incorporation into the legislative acts. CONCLUSION It is desirable that ethical instruments become legally binding documents, because only in this way will be possible to control all phases of the clinical trials and prevent abuse of the respondents.